Anti-PM-Scl antibodies in myositis


Authors: L. Pleštilová 1,2;  J. Vencovský 1
Authors‘ workplace: Revmatologický ústav, Praha 1;  6. ročník, 3. lékařská fakulta, Univerzita Karlova, Praha 2
Published in: Čes. Revmatol., 17, 2009, No. 4, p. 200-204.
Category: Overview Reports

Overview

Anti-PM-Scl antibodies are most frequently found in patients with overlap syndrome of polymyositis and systemic sclerosis (31%), less frequently in myositis alone (8–11%), or systemic sclerosis (2%). Detection of these antibodies is associated with better outcome of the disease, which usually responds well to the treatment with low- to medium-dose glucocorticoids. The “human exosome” is a PM-Scl autoantigen, a macromolecular complex of 11–16 polypeptides, which is involved in the degradation of precursor rRNA in the nucleolus and in the degradation of mature mRNA in the cytoplasm. Antibody response against the PM-Scl complex is primarily targeted against the PM-Scl-100 protein, the main epitope of which is PM1-α peptide.

Key words:
myositis, systemic sclerosis, exosome, anti-PM-Scl, PM1-α


Sources

1. Brouwer R, Hengstman GJ, Vree Egberts W, Ehrfeld H, Bozic B, Ghirardello A, et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001;60:116-23.

2. Vencovský J. Diferenciální diagnostika a léčba idiopatických zánětlivých myopatií. Interní medicína pro praxi 2005;11:480-483

3. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003;362(9388):971-82.

4. Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Senécal JL. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 2007;9:R78.

5. Wada K, Kamitani T. Autoantigen Ro52 is an E3 ubiquitin ligase. Biochem Biophys Res Commun 2006;339:415-21.

6. Belisova A, Semrad K, Mayer O, Kocian G, Waigmann E, Schroeder R, et al. RNA chaperone activity of protein components of human Ro RNPs. RNA 2005;11:1084-94.31.

7. Seiberlich B, Hunzelmann N, Roers A, Weber M , Schulze-Lohoff E. Das Jo-1-Syndrom und seine klinischen Manifestationen. Medizinische Klinik 2005;100:137-142

8. Mahler M, Raijmakers R. Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights. Autoimmun Rev 2007;6:432-7.

9. Marguerie C, Bunn CC, Copier J, Bernstein RM, Gilroy JM, Black CM, et al. The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl. Medicine (Baltimore) 1992;71:327-36.

10. Mahler M, Fritzler MJ. PM1-Alpha ELISA: the assay of choice for the detection of anti-PM/Scl autoantibodies? Autoimmun Rev 2009;8:373-8.

11. O‘Hanlon TP, Carrick DM, Targoff IN, Arnett FC, Reveille JD, Carrington M, et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore) 2006;85:111-27.

12. Jury EC, D‘Cruz D, Morrow WJ. Autoantibodies and overlap syndromes in autoimmune rheumatic disease. J Clin Pathol 2001;54:340-7.

13. Mahler M, Raijmakers R, Dähnrich C, Blüthner M, Fritzler MJ. Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen. Arthritis Res Ther 2005;7:R704-13.

14. Brouwer R, Pruijn GJ, van Venrooij WJ. The human exosome: an autoantigenic complex of exoribonucleases in myositis and scleroderma. Arthritis Res 2001;3:102-6.

15. Brouwer R, Vree Egberts WT, Hengstman GJ, Raijmakers R, van Engelen BG, Seelig HP, et al. Autoantibodies directed to novel components of the PM/Scl complex, the human exosome. Arthritis Res 2002;4:134-8.

16. Rodenburg RJ, Raats JM, Pruijn GJ, van Venrooij WJ. Cell death: a trigger of autoimmunity? Bioessays 2000;22 (7):627-36.

17. Mahler M, Blüthner M, Pollard KM. Advances in B-cell epitope analysis of autoantigens in connective tissue diseases. Clin Immunol 2003;107(2):65-79.

18. Blüthner M, Mahler M, Müller DB, Dünzl H, Bautz FA. Identification of an alpha-helical epitope region on the PM/Scl-100 autoantigen with structural homology to a region on the heterochromatin p25beta autoantigen using immobilized overlapping synthetic peptides. J Mol Med 2000;78(1):47-54.

19. Hanke K, Brückner CS, Dähnrich C, Huscher D, Komorowski L, Meyer W, et al. Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients. Arthritis Res Ther 2009;11(1):R22.

20. Mahler M, Fritzler MJ. The changing landscape of the clinical value of the PM/Scl autoantibody system. Arthritis Res Ther 2009;11(2):106.

Labels
Dermatology & STDs Paediatric rheumatology Rheumatology
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account